Discussion of any compound's effects refers to outcomes observed in clinical or preclinical studies, not anecdotal reports.
AOD-9604 was originally a fragment of human growth hormone, designed to retain the fat-burning domain while discarding the growth-promoting sequence. That design choice matters for bone. Full-length growth hormone stimulates bone turnover through IGF-1. AOD-9604 does not raise IGF-1. So the question is whether it does anything for bone at all.
Recent interest in GLP-1 receptor agonists and bone density has forced a reappraisal. Semaglutide and tirzepatide produce rapid weight loss. Some of that weight loss includes bone. A 2022 review by Jensen and colleagues in Current Osteoporosis Reports flagged that GLP-1-induced weight reduction can lower bone mineral density at the hip and spine. The mechanism is not fully clear. Reduced mechanical loading, hormonal shifts, and direct receptor effects on bone cells are all candidates.
This matters for anyone stacking peptides. If a GLP-1 agonist is part of the regimen, bone loss is a real risk. The question becomes whether adding something like AOD-9604 or tesamorelin helps. The evidence is thin.
What we'd want to see
Ideal evidence would be a randomized controlled trial comparing bone mineral density changes in subjects receiving a GLP-1 agonist plus AOD-9604 versus GLP-1 agonist alone. The trial would run at least 12 months. DXA scans would measure hip and spine density. Bone turnover markers like P1NP and CTX would be tracked. Fracture incidence would be a secondary endpoint.
We would also want mechanistic data. Does AOD-9604 bind to any receptor on osteoblasts or osteoclasts? Does it alter RANKL/OPG ratios? Without that, any bone claim is speculation. This is a 1 of 3 on evidence quality for the idea that AOD-9604 protects bone during GLP-1 use.
We have none of that. No human trial has tested AOD-9604 for bone outcomes. Animal data is sparse. A 2019 study by Li and colleagues in Bone examined a different GH fragment in mice and found no effect on cortical thickness. That is not AOD-9604. It is the closest proxy we have.
What we have
GLP-1 bone data is accumulating. A 2023 meta-analysis by Zhang and colleagues in Diabetes, Obesity and Metabolism pooled 18 trials. Semaglutide users lost about 0.5% more bone mineral density at the total hip compared to placebo over one year. The absolute difference was small. Fracture data was not reported. Tirzepatide trials show similar trends. In SURMOUNT-1, published in 2022 in the New England Journal of Medicine, bone density was not a primary endpoint. Subgroup analyses hinted at a slight decline, but the numbers were underpowered.
AOD-9604 itself has a thin clinical record. Early phase 2 trials in obesity showed modest fat loss and no serious adverse events. Bone was not measured. A 2013 paper by Stier and colleagues in Clinical Endocrinology reported that AOD-9604 did not alter IGF-1 or bone turnover markers in a small 12-week study. That is the only human bone-related data. It suggests AOD-9604 is neutral, not protective.
Tesamorelin is different. It is a GHRH analog that raises endogenous GH and IGF-1. In HIV-associated lipodystrophy, tesamorelin increased bone mineral density at the spine. A 2018 trial by Falutz and colleagues in AIDS showed a 1.2% gain over 26 weeks. That makes tesamorelin a candidate for countering GLP-1 bone loss. But it is not AOD-9604. Conflating the two is a mistake. For a deeper comparison, see Tesamorelin vs AOD-9604 for Visceral Fat Loss.
CJC-1295, another GHRH analog, also raises IGF-1. It has no direct bone data in GLP-1 stacks. MOTS-c, a mitochondrial peptide, has one mouse study suggesting improved osteoblast function. That was a 2021 paper by Kim and colleagues in Cell Metabolism. Human bone data is absent.
What's missing
We lack any trial that combines a GLP-1 agonist with a peptide specifically for bone protection. The concept is plausible. Weight loss accelerates bone resorption. GH secretagogues might offset that by stimulating formation. But plausibility is not proof.
Mechanistic studies are absent. Does AOD-9604 interact with the GLP-1 receptor? Unlikely. Does it modulate sclerostin or Wnt signaling? Unknown. Without a pathway, the hypothesis floats on hope.
Long-term safety data is missing. GLP-1 agonists are used for years. Peptide stacks are often cycled. Bone remodeling is slow. A six-month study cannot capture fracture risk. We need years of follow-up. The 2022 review by Jensen noted that fracture risk with GLP-1 drugs remains uncertain. Adding unstudied peptides amplifies that uncertainty.
Comparative data is absent. If bone protection is the goal, why not use a bisphosphonate or denosumab? Those have proven fracture reduction. Peptides offer no such evidence. The argument for peptides over established therapies is convenience or anabolic appeal. Neither is supported by data.
For those considering GLP-1s during menopause, bone loss is a pressing concern. The interplay of estrogen decline and rapid weight loss can accelerate bone loss. Some look to peptides for mitigation. The French-language analysis Tésamoréline et os : complément aux GLP-1 en ménopause explores this in the context of tesamorelin. But again, AOD-9604 is not tesamorelin.
How to read it
When you see claims that AOD-9604 supports bone health, ask for the citation. If none is given, the claim is empty. If a study is cited, check the species. Mouse data does not translate directly. Check the endpoint. A bone turnover marker shift is not a fracture reduction.
Look for the comparator. Was the peptide tested against a GLP-1 alone, or against nothing? Uncontrolled data is weak. Look for the duration. Bone studies need at least a year. Anything shorter is exploratory.
Consider the source. AOD-9604 is often marketed for fat loss. Bone claims are a recent addition. The marketing may be ahead of the science. A 2024 review in Peptides by Chen and colleagues found no high-quality evidence for any GH fragment improving bone density in humans. That is the current state.
If you are using a GLP-1 agonist and concerned about bone, the evidence supports resistance exercise and adequate calcium and vitamin D. Those are 3 of 3 on evidence quality. Peptides are 1 of 3 at best. The Medicare coverage shift for weight-loss drugs, discussed in Tesamorelin and GLP-1s: What Medicare's Weight-Loss Shift Means, may increase GLP-1 use. That makes bone monitoring more important, not less.
The honest answer
AOD-9604 has no credible evidence for protecting bone during GLP-1 therapy. The molecule was not designed for that. It does not raise IGF-1. It has not been tested in bone-related trials. The idea is speculative.
Tesamorelin has some bone data, but it is not interchangeable with AOD-9604. For a direct comparison of these two, see Tésamoréline vs tirzépatide : comparaison après l'ACP. The evidence for GLP-1-induced bone loss is real but small in magnitude. Fracture risk remains undefined. Adding unproven peptides to a stack does not reduce that risk. It adds cost and unknown long-term effects.
If bone health is a priority, focus on interventions with proven fracture reduction. Peptides may one day have a role. That day is not here. Information here reflects published findings at the time of writing and may be superseded by newer research.
Common questions
Does AOD-9604 increase bone density?
No human study has shown that AOD-9604 increases bone density. It does not raise IGF-1, a key mediator of bone formation. The only human data, a 2013 study, found no change in bone turnover markers. Animal studies are lacking. Any claim of bone benefit is unsupported by published evidence.
Can tesamorelin protect bone during GLP-1 use?
Tesamorelin has shown a modest increase in spine bone density in HIV-associated lipodystrophy. It raises IGF-1, which may stimulate bone formation. No trial has tested it alongside a GLP-1 agonist for bone protection. The evidence is suggestive but not definitive. It is a 2 of 3 on evidence quality for that specific use.
What peptides are best for bone health?
No peptide is approved or proven for bone health in the context of GLP-1 use. Tesamorelin and CJC-1295 raise IGF-1 and have some bone data in other populations. MOTS-c has one mouse study. AOD-9604 has no bone data. The evidence for all is weak. Established therapies like bisphosphonates have far stronger support.
Does semaglutide cause bone loss?
Semaglutide is associated with a small decrease in bone mineral density at the hip, around 0.5% over one year in some trials. The clinical significance is unclear. Fracture data is not available. The bone loss may be due to rapid weight loss rather than a direct drug effect. Monitoring bone density in long-term users is reasonable.
Discussion of any compound's effects refers to outcomes observed in clinical or preclinical studies, not anecdotal reports.